This week's Fierce Biotech is brought to you by Crown Bioscience.

Trouble viewing? Click here.



Dear E,

Want to progress your myeloid and TME-targeting immuno-oncology drugs with confidence?

Discover the benefits of the 3D high content imaging solution in our TechTalk:

  • Visualize and quantify immunotherapy and TME effects on myeloid cells using a robust 3D phenotypic analysis

  • Analyze myeloid cells cultured in 3D better resembling the physiological environment in vivo

  • Accurately measure the functional reprogramming of the suppressive tumor-associated macrophage population towards an M1 phenotype induced by drug candidates

  • Understand drug effects in a suppressive TME in both monocultures of myeloid cells and co-cultures of myeloid cells and tumoroids with an option to include T cells through functional readouts including tumoroid killing and immune cell infiltration

In this TechTalk, Dr. Gera Goverse discusses how the incorporation of different myeloid cell populations results in a better representation of the human immune system in the tumor microenvironment (TME) in 3D image-based co-cultures of tumor and immune cells. Discover our 3D high content imaging assay to visualize and quantify immunotherapy and TME effects on myeloid cells using 3D phenotypic analysis.

© 2021 Crown Bioscience Inc.

Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact aalcover@questex.com or call 202-824-5074.



You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Questex, LLC
685 3rd Avenue, 21st Floor  
New York, NY 10017